167 MET, ECD shedding, and loss of E-cadherin Supplementary table 14: Sensitivity, specificity, positive predictive and negative predictive value, accuracy and AUC of ECD shedding within the D1C2 uniform positive staining pattern in view of survival analyses with respect to OS for patients showing overall more C- than N-terminal MET immunoreactivity (n=152). Positive test result was set at ≥ 6.25% ECD shedding Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) AUC (95% CI) Cancers showing overall more C- than N-terminal MET immunoreactivity 61.3 67.8 56.7 71.8 65.1 0.65 (0.56; 0.74) Supplementary table 15: Results of performed ROC curve analyses in view of determining the cut off for percentage of cancer cells showing ECD shedding within the D1C2 uniform positive staining pattern in view of survival analyses for DFS for patients showing overall more C- than N-terminal MET immunoreactivity using Youden’s J statistic (n=152). Area Std. error Asymptotic sig. Asymptotic 95% confidence interval Lower bound Upper bound Results ROC curve used to determine the maximal value of the Youden index to determine the optimal cutoff for % of cancer cells showing ECD shedding within the D1C2 uniform positive staining pattern in view of survival analyses 0.62 0.046 0.011 0.53 0.71 Results ROC curve obtained using the optimal cut off of 6.25 cancer cells showing ECD shedding 0.63 0.045 0.007 0.54 0.72 Supplementary table 16: Sensitivity, specificity, positive predictive and negative predictive value, accuracy and AUC of ECD shedding within the D1C2 uniform positive staining pattern in view of survival analyses with respect to DFS for patients showing overall more C- than N-terminal MET immunoreactivity (n=152). Positive test result was set at ≥ 6.25 % ECD shedding Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%) AUC (95% CI) Cancers showing overall more C- than N-terminal MET immunoreactivity 56.4 68.9 65.7 60.0 62.5 0.63 (0.54; 0.72) 5
RkJQdWJsaXNoZXIy MTk4NDMw